Eq Rx just raised. Here's exactly what to do next.
Who to reach, what to say, and why now — on Eq Rx , plus every funding round, exec hire, and M&A move that follows, each with verified, ICP-ranked contacts.
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Get the full Deep Dive on Eq Rx — free.
We'll email your report. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Everyone else gives you a piece
Only Fundz delivers all four.
EQRx Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing
Amount Raised
$500 Million
Round Type
series b
Description
EQRx, a company committed to developing and delivering important new medicines at lower prices, today announced that it has raised $500 million in Series B financing. Since launching a year ago, EQRx has raised approximately $750 million to advance its mission of bringing new medicines to treat life-threatening and chronic diseases to patients and healthcare systems around the world at prices that are a fraction of the cost of today’s leading therapies.
Funding Insights
Based on industry dataWatching Eq Rx ? See every signal — funding, hires, M&A, contracts, sentiment.
Request a demoChoose your plan